ER+ and PR+ Breast Cancer: Key Statistics and Molecular Insights
ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...
pharmaphorum6d
Pfizer's new drug data in breast cancer draws muted response
Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...
Nature2mon
An issue of tissues: divining the split personalities of selective estrogen receptor modulators
Figure 1: Nuclear receptor co-regulators modulate the transcriptional potential of estrogen receptor activated ... ER signaling pathways to confer a selective advantage in tumor progression.
FierceBiotech6d
Pfizer, Arvinas post mixed breast cancer survival results in first phase 3 test for a PROTAC degrader
Pfizer and Arvinas’ estrogen receptor (ER) degrader has failed a key part of its first phase 3 test, although the companies have pointed to success in a subpopulation to suggest the therapy ...
Nasdaq6d
Arvinas and Pfizer Announce Positive Phase 3 VERITAC-2 Trial Results for Vepdegestrant in Estrogen Receptor 1-Mutant Advanced Breast Cancer
Vepdegestrant is an investigational, orally bioavailable PROTAC (PROteolysis TArgeting Chimera) protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the ...